This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Access Pharmaceuticals, Inc., provided an update today on the progress in the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.
We care about your feedback. Let us know how we can improve your CancerCompass experience.